XW043MA
XW043MA — Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10
Billable / specific codeICD-10-PCS
CMS abbreviated title: Introduce Emapalumab-lzsg in Central Vein, Perc, New Tech 10
How XW043MA is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- WBody systemWhich system it acts on
- 0Root operationThe objective — the verb of the procedure
- 4Body partThe specific site
- 3ApproachHow the site was reached
- MDeviceWhat was left in place, if anything
- AQualifierA further distinction where one applies
Codes near XW043MA
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XW043H6Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
- XW043H7Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043J7Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043K7Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043K9Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
- XW043L6Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
- XW043L7Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043M7Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043MAIntroduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10
- XW043N7Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
- XW043NAIntroduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
- XW043P9Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
- XW043PBIntroduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
- XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
- XW043Q9Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
- XW043QBIntroduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
- XW043R9Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9